Health Canada – federal authority overseeing medical devices
Through its Medical Devices Bureau within the Health Products and Food Branch, Health Canada authorises and monitors medical devices on the Canadian market. The agency reviews documentation, verifies regulatory compliance, supervises inspections and enforces distribution requirements. Market approval is only the start: the product remains under continuous post-market oversight once it is in commerce.
The Canadian four-class device-risk system
Health Canada classifies devices into four risk-based categories:
| Class | Risk level |
|---|---|
| Class I | low risk |
| Class II | low-to-moderate risk |
| Class III | moderate-to-high risk |
| Class IV | high risk |
The class determines both the registration pathway and the depth of documentation. Class I products require only an establishment licence (MDEL), whereas Classes II–IV need an individual Medical Device Licence (MDL) plus MDSAP certification, described below. In-vitro diagnostics follow the same structure, with risk determined largely by the device’s IVD performance evaluation – the higher the clinical and diagnostic risk this evaluation reveals, the stricter the Canadian registration pathway.
Two registration routes – MDEL versus MDL
Canada operates parallel licensing systems, depending on device class and supply-chain role.
Medical Device Establishment Licence (MDEL)
An MDEL is a site licence for distributors, importers and manufacturers of Class I devices. Applicants must implement Quality Management System (QMS) procedures and comply with Good Distribution Practices (GDP). Documentation must demonstrate that the company can monitor and control devices throughout the supply chain, even if it does not manufacture them.
Medical Device Licence (MDL)
An MDL is a product-specific licence for Class II, III and IV devices. Health Canada reviews classification, technical data, declaration of conformity, labels, IFU and compliance with the Canadian Medical Devices Regulations (CMDR). Classes III and IV must also submit detailed clinical and quality data plus a valid MDSAP certificate – since 2019, Health Canada no longer accepts a standalone ISO 13485 certificate issued outside this program (see the next section for details).
CE-marked products may leverage existing technical dossiers, but a European Notified Body’s ISO 13485 certificate does not substitute for MDSAP certification – a separate MDSAP audit, or an extension of the existing quality system to cover this scope, is required.
MDSAP audit – mandatory QMS certification for Class II–IV
The Medical Device Single Audit Program (MDSAP) is a harmonised international audit framework in which a single quality management system audit, based on ISO 13485:2016 and conducted by an approved Auditing Organization (AO), is recognised simultaneously by five regulatory authorities: Health Canada, the US FDA, Australia’s TGA, Brazil’s ANVISA and Japan’s MHLW/PMDA.
Since 1 January 2019, Health Canada has required a valid MDSAP certificate as a condition for issuing and renewing an MDL for Class II, III and IV devices – a standalone ISO 13485 certificate (for example, one issued solely for the EU market) is not sufficient. Notably, Canada is the only MDSAP participating country to have made this certification fully mandatory – the other program countries treat MDSAP as an accepted alternative rather than a hard requirement.
In practice, this means:
- the audit must be conducted by a body holding recognised Auditing Organization status under MDSAP (currently around 15 recognised AOs) – not every ISO 13485 certification body holds this status,
- the MDSAP audit scope is broader than a standard ISO 13485 audit, covering additional regulatory requirements from the participating countries,
- an MDSAP certificate can be used simultaneously for registration in the US, Australia, Brazil and Japan — relevant when planning a multi-market strategy,
- certification typically takes longer than a conventional ISO 13485 audit and should be planned well ahead of the registration timeline,
- in February 2026, the MDSAP Audit Approach was revised (AU P0002.010) to align with the FDA’s new Quality Management System Regulation (QMSR) – worth factoring into any audit planned for 2026 or 2027.
Source and full program documentation: Health Canada – Medical Device Single Audit Program (MDSAP).
Who can apply for an MDEL or MDL?
Both domestic and foreign manufacturers can hold MDELs or MDLs. Unlike the EU or the USA — where a foreign manufacturer needs an EU Authorised Representative or a U.S. Agent – Canada does not mandate an authorised representative. A foreign producer may apply directly, provided it meets all system and document requirements.
Importers, however, must hold their own MDEL and comply with GDP, regardless of supplier location. Legal responsibility for the product is not automatically transferred.
IVD specifics in Canada
IVDs follow the same licensing logic: Class I only needs an MDEL, while Classes II–IV require an MDL together with MDSAP certification. Submissions must include performance-validation data, matrix-interference studies and bilingual (English & French) labels and IFUs.
Additional evidence may be requested for home-use tests, prenatal diagnostics or products containing human-derived materials.
Post-licence obligations
Licence holders must keep data current, report incidents and maintain records under Health Canada rules. Technical changes, manufacturer or distributor switches, or IFU updates can trigger amendment applications.
Health Canada performs scheduled and for-cause inspections, renews MDELs annually (typically by 1 April), and expects MDSAP certificates to remain valid throughout the licence period. Non-compliance can suspend a licence, delay shipments or force recalls.
How Pure Clinical streamlines Canadian MD and IVD registration
Canada’s pathway may look simpler than EU or FDA routes, yet it hides unique procedural and documentary nuances – MDSAP being the clearest example. Pure Clinical supports both foreign and domestic firms throughout the MDEL and MDL process, aligned with Health Canada guidance.
Our services include:
- risk-based classification of MDs and IVDs under CMDR,
- preparing MDEL applications with QMS & GDP procedures,
- compiling Class II–IV MDL technical dossiers,
- pre-audit preparation and coordination with a recognised MDSAP Auditing Organization,
- verifying bilingual labels and IFUs for compliance,
- liaising with Health Canada and tracking submission status,
- pre-submission gap audits to ensure dossier readiness.
Partnering with North-American affiliates, we accelerate approvals even for high-risk devices or IVDs requiring extensive clinical evidence.
FAQ
Does registering a medical device in Canada require a local representative?
What’s the difference between an MDEL and an MDL?
Is an ISO 13485 certificate from an EU Notified Body enough to register in Canada?